Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
Letter requests an immediate amendment to the PREP Act declaration on COVID-19, which would allow pharmacists to order and administer REGEN-COV and future authorized products for the treatment of COVID-19.
On July 28, AMCP provided comments on PQA's prospective strategic and broad-reaching goals.
On July 28, AMCP signed a Medicare Part D stakeholder letter urging HHS to extend the Enhanced Medication Therapy Management (EMTM) Model which is currently set to expire on December 31, 2021.
Joint Statement in Support of COVID-19 Vaccine Mandates for All Workers in Health and Long-Term Care
On July 26, AMCP joined other health care organizations in a joint statement in support of COVID-19 Vaccine mandates for all workers in health and long-term care.
AMCP submitted comments on a Office of Management and Budget request for information on advancing equity in underserved communities through government.
On June 14, AMCP submitted comments on the Medicare Part D Medication Therapy Management Program's Standardized Format for the comprehensive medication review.
On May 25, AMCP joined Medicare stakeholder organizations in thanking Congressional members for introducing the Pharmacy and Medically Underserved Areas Enhancement Act (H.R. 2759/S.1362).
AMCP sent a letter to the Department of Health and Human Services Office of the Inspector General on changes to the federal anti-kickback statute.
On April 28, AMCP sent a letter of support to the Senate for Chiquita Brooks-LaSure's nomination to be CMS Administrator.
AMCP submitted a letter on the reopened comment period for the Medicaid Coverage of Innovative Technologies rule, which created a pathway for fast national Medicare coverage of innovative technologies, including digital therapeutics.
On April 19, AMCP submitted joint recommendations to CMS on Medicare Advantage enrollees seeking COVID-19 vaccine without their Original Medicare card. CMS is recommended to present clear guidance to all vaccination sites and providers and instruct MACs to provide assistance to providers to ensure vaccine administration is accurately reimbursed and entered into the COVAX portal.
On March 16, AMCP joined Medicare stakeholders in urging House and Senate leadership to swiftly repeal the 2020 Medicare Part D rebate rule using Congressional Review Act authority.
